KR20250021614A - 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법 - Google Patents

염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법 Download PDF

Info

Publication number
KR20250021614A
KR20250021614A KR1020257002822A KR20257002822A KR20250021614A KR 20250021614 A KR20250021614 A KR 20250021614A KR 1020257002822 A KR1020257002822 A KR 1020257002822A KR 20257002822 A KR20257002822 A KR 20257002822A KR 20250021614 A KR20250021614 A KR 20250021614A
Authority
KR
South Korea
Prior art keywords
cd32b
cd79b
ser
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257002822A
Other languages
English (en)
Korean (ko)
Inventor
웨이 첸
폴 에이. 무어
내미쉬 바라트 판디야
에지오 본비니
존 마크 위깅턴
Original Assignee
마크로제닉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크로제닉스, 인크. filed Critical 마크로제닉스, 인크.
Publication of KR20250021614A publication Critical patent/KR20250021614A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257002822A 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법 Pending KR20250021614A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662346717P 2016-06-07 2016-06-07
US62/346,717 2016-06-07
US201662432328P 2016-12-09 2016-12-09
US62/432,328 2016-12-09
PCT/US2017/036079 WO2017214096A1 (en) 2016-06-07 2017-06-06 Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders
KR1020227034973A KR20220143769A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034973A Division KR20220143769A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법

Publications (1)

Publication Number Publication Date
KR20250021614A true KR20250021614A (ko) 2025-02-13

Family

ID=60578080

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257002822A Pending KR20250021614A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법
KR1020227034973A Ceased KR20220143769A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법
KR1020197000362A Ceased KR20190016079A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227034973A Ceased KR20220143769A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법
KR1020197000362A Ceased KR20190016079A (ko) 2016-06-07 2017-06-06 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법

Country Status (11)

Country Link
US (1) US20190322741A1 (cg-RX-API-DMAC10.html)
EP (1) EP3464378A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019521103A (cg-RX-API-DMAC10.html)
KR (3) KR20250021614A (cg-RX-API-DMAC10.html)
CN (1) CN109311990A (cg-RX-API-DMAC10.html)
AU (1) AU2017278329B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075303A2 (cg-RX-API-DMAC10.html)
MX (2) MX2018015265A (cg-RX-API-DMAC10.html)
RU (1) RU2022101891A (cg-RX-API-DMAC10.html)
TW (1) TW201742633A (cg-RX-API-DMAC10.html)
WO (1) WO2017214096A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
JP2022513338A (ja) * 2018-10-03 2022-02-07 ネペンザ・バイオサイエンシズ・エルエルシー 抗ｃｄ７９抗体およびその使用
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
KR20220091458A (ko) * 2019-07-30 2022-06-30 프로벤션 바이오, 인코포레이티드 비-고갈성 b 세포 억제제에 의한 면역원성을 감소시키기 위한 방법 및 조성물
WO2021207681A1 (en) * 2020-04-10 2021-10-14 The Board Of Trustees Of The Leland Stanford Junior University Targeted reduction of activated immune cells
KR20230113312A (ko) * 2020-11-01 2023-07-28 프로벤션 바이오, 인코포레이티드 루푸스 치료 방법 및 조성물
CA3231174A1 (en) * 2021-08-02 2023-02-09 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd79bxcd3 bispecific antibody and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
AU2016207758C1 (en) * 2015-01-13 2020-05-28 New Zealand Institute For Bioeconomy Science Limited Agricultural composition

Also Published As

Publication number Publication date
US20190322741A1 (en) 2019-10-24
JP2019521103A (ja) 2019-07-25
RU2022101891A (ru) 2022-02-07
BR112018075303A2 (pt) 2019-04-30
RU2018145971A3 (cg-RX-API-DMAC10.html) 2020-09-03
AU2017278329B2 (en) 2024-08-08
MX2018015265A (es) 2019-09-06
KR20220143769A (ko) 2022-10-25
KR20190016079A (ko) 2019-02-15
WO2017214096A1 (en) 2017-12-14
RU2018145971A (ru) 2020-07-10
CN109311990A (zh) 2019-02-05
JP2022120061A (ja) 2022-08-17
TW201742633A (zh) 2017-12-16
EP3464378A1 (en) 2019-04-10
JP2024102146A (ja) 2024-07-30
EP3464378A4 (en) 2020-06-17
MX2024005841A (es) 2024-05-27
AU2017278329A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
KR102294018B1 (ko) CD32B 및 CD79b에 결합할 수 있는 이중특이성 1가 Fc 디아바디 및 그것의 용도
US20190002563A1 (en) Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
AU2015321546B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
JP2024102146A (ja) 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子
CN107614013B (zh) 结合lag-3的分子和其使用方法
KR20210091710A (ko) PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
JP2019517539A (ja) 併用療法
ES3056908T3 (en) Adam9-binding molecules, and methods of use thereof
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
US20170157251A1 (en) Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
US20250215081A1 (en) Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20220133196A (ko) 면역 세포 관여 효과를 조절하기 위한 수단 및 방법
US20210246194A1 (en) Optimized gp41-Binding Molecules and Uses Thereof
AU2023259161A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
RU2772434C2 (ru) Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
HK40113244A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250124

Application number text: 1020227034973

Filing date: 20221007

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250219

Comment text: Request for Examination of Application